Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026337 · ClinicalTrials.gov registry record
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 43
- Enrollment target
NCT01026337: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01026337 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026337 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.
Interventions
- GENETIC mutation analysis
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-04 |
| Est. Completion | 2018-11 |
What the finished NCT01026337 record still lists
NCT01026337 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which mutation analysis is the first listed.
NCT01026337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01026337 about?
NCT01026337 is a clinical study titled "Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer". Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.
What is the current status of trial NCT01026337?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2009-04. Estimated completion is 2018-11.
What interventions are being tested in trial NCT01026337?
The interventions under investigation include: mutation analysis (GENETIC), immunohistochemistry staining method (OTHER), pharmacological study (OTHER), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT01026337?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia